These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 28078663)

  • 1. Inhibition of heat shock protein 90 exerts an antitumour effect in angiosarcoma: involvement of the vascular endothelial growth factor signalling pathway.
    Yamada-Kanazawa S; Kajihara I; Fukushima S; Jinnin M; Masuzawa M; Masuzawa M; Amoh Y; Hoshina D; Abe R; Ihn H
    Br J Dermatol; 2017 Aug; 177(2):456-469. PubMed ID: 28078663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib.
    Nagaraju GP; Mezina A; Shaib WL; Landry J; El-Rayes BF
    Eur J Cancer; 2016 Jan; 52():109-19. PubMed ID: 26682870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heat shock protein 90 (HSP90) is overexpressed in p16-negative oropharyngeal squamous cell carcinoma, and its inhibition in vitro potentiates the effects of chemoradiation.
    Patel K; Wen J; Magliocca K; Muller S; Liu Y; Chen ZG; Saba N; Diaz R
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):1015-22. PubMed ID: 25205430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PDK1 is a potential therapeutic target against angiosarcoma cells.
    Wada M; Horinaka M; Yasuda S; Masuzawa M; Sakai T; Katoh N
    J Dermatol Sci; 2015 Apr; 78(1):44-50. PubMed ID: 25726712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting heat-shock protein 90 with ganetespib for molecularly targeted therapy of gastric cancer.
    Liu H; Lu J; Hua Y; Zhang P; Liang Z; Ruan L; Lian C; Shi H; Chen K; Tu Z
    Cell Death Dis; 2015 Jan; 6(1):e1595. PubMed ID: 25590805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor Suppression Efficacy of Heat Shock Protein 90 Inhibitor 17AAG in a Liposarcoma Mouse Model.
    Nam S; Kim H; Hong D; Park JB; Kim SJ
    Anticancer Res; 2017 Nov; 37(11):6291-6302. PubMed ID: 29061812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of heat shock protein 90 in migration and proliferation of vascular smooth muscle cells in the development of atherosclerosis.
    Kim J; Jang SW; Park E; Oh M; Park S; Ko J
    J Mol Cell Cardiol; 2014 Jul; 72():157-67. PubMed ID: 24650873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis.
    Acquaviva J; He S; Sang J; Smith DL; Sequeira M; Zhang C; Bates RC; Proia DA
    Mol Cancer Res; 2014 May; 12(5):703-13. PubMed ID: 24554781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors.
    Gloesenkamp C; Nitzsche B; Lim AR; Normant E; Vosburgh E; Schrader M; Ocker M; Scherübl H; Höpfner M
    Int J Oncol; 2012 May; 40(5):1659-67. PubMed ID: 22246317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic effects of inhibition of heat shock protein 90 (HSP90) in human pancreatic and colon cancer.
    Nagaraju GP; Wu C; Merchant N; Chen Z; Lesinski GB; El-Rayes BF
    Cancer Lett; 2017 Aug; 402():110-116. PubMed ID: 28583846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.
    Rouhi A; Miller C; Grasedieck S; Reinhart S; Stolze B; Döhner H; Kuchenbauer F; Bullinger L; Fröhling S; Scholl C
    Oncotarget; 2017 Jan; 8(5):7678-7690. PubMed ID: 28032595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
    Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
    Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and Evaluation of a Novel Deguelin Derivative, L80, which Disrupts ATP Binding to the C-terminal Domain of Heat Shock Protein 90.
    Lee SC; Min HY; Choi H; Kim HS; Kim KC; Park SJ; Seong MA; Seo JH; Park HJ; Suh YG; Kim KW; Hong HS; Kim H; Lee MY; Lee J; Lee HY
    Mol Pharmacol; 2015 Aug; 88(2):245-55. PubMed ID: 25976766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib.
    Landmann H; Proia DA; He S; Ogawa LS; Kramer F; Beißbarth T; Grade M; Gaedcke J; Ghadimi M; Moll U; Dobbelstein M
    Cell Death Dis; 2014 Sep; 5(9):e1411. PubMed ID: 25210794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heat shock protein 90 inhibitor mycoepoxydiene modulates kinase signaling in cervical cancer cells and inhibits in-vivo tumor growth.
    Lin P; Yi Y; Lu M; Wang M; Yang Y; Lu Y; Song S; Zheng Z; Deng X; Zhang L
    Anticancer Drugs; 2015 Jan; 26(1):25-34. PubMed ID: 25014191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Taxotere-induced inhibition of human endothelial cell migration is a result of heat shock protein 90 degradation.
    Murtagh J; Lu H; Schwartz EL
    Cancer Res; 2006 Aug; 66(16):8192-9. PubMed ID: 16912198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined inhibition of heat shock proteins 90 and 70 leads to simultaneous degradation of the oncogenic signaling proteins involved in muscle invasive bladder cancer.
    Cavanaugh A; Juengst B; Sheridan K; Danella JF; Williams H
    Oncotarget; 2015 Nov; 6(37):39821-38. PubMed ID: 26556859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Network analysis identifies an HSP90-central hub susceptible in ovarian cancer.
    Liu H; Xiao F; Serebriiskii IG; O'Brien SW; Maglaty MA; Astsaturov I; Litwin S; Martin LP; Proia DA; Golemis EA; Connolly DC
    Clin Cancer Res; 2013 Sep; 19(18):5053-67. PubMed ID: 23900136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down-regulation of ERK1/2 and AKT-mediated X-ray repair cross-complement group 1 protein (XRCC1) expression by Hsp90 inhibition enhances the gefitinib-induced cytotoxicity in human lung cancer cells.
    Tung CL; Jian YJ; Syu JJ; Wang TJ; Chang PY; Chen CY; Jian YT; Lin YW
    Exp Cell Res; 2015 May; 334(1):126-35. PubMed ID: 25662161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
    Schwock J; Pham NA; Cao MP; Hedley DW
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.